Tag: common stock

NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- Keel Infrastructure Corp. (NASDAQ/TSX: KEEL), a North American digital and energy infrastructure company (“Keel” or the “Company”), today announced that it has priced its offering of $400 million aggregate principal amount of 1.250% convertible senior notes due 2032 (the “Convertible Notes”). Keel has also granted the initial purchasers of the Convertible Notes an option to purchase, for a 13-day period beginning on and including the date on which the Convertible Notes are first issued, up to an additional $58 million aggregate principal amount of the Convertible Notes. The aggregate principal amount of the offering was increased from the previously announced offering size of $350 million (or $408 million if the initial purchasers exercise their option to purchase the option in full). The payment obligations under the notes will be fully and unconditionally guaranteed, on a senior unsecured basis, by Bitfarms Ltd., a wholly owned subsidiary of Keel. The offering is expected to close, subject to market and other closing conditions on or about June 9, 2026.

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Helen of Troy Limited (NASDAQ: HELE) between April 24, 2024 and October 8, 2025, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 3, 2026.

BALLERUP, Denmark, June 04, 2026 (GLOBE NEWSWIRE) -- LiqTech International, Inc. (NASDAQ: LIQT), a clean technology company specializing in advanced ceramic filtration solutions, today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $1.00 per share for aggregate gross proceeds of approximately $20 million, prior to deducting underwriting discounts, commissions and other offering expenses. In addition, the Company has granted the underwriter a 45-day option to purchase up to an additional 3,000,000 shares of common stock at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any. The offering is expected to close on June 8, 2026, subject to satisfaction of customary closing conditions.

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of LKQ Corporation (NASDAQ: LKQ) between February 27, 2023 and July 23, 2025, both dates inclusive (the “Class Period”), of the important June 22, 2026 lead plaintiff deadline.

SAN DIEGO, June 04, 2026 (GLOBE NEWSWIRE) -- SOLV Energy, Inc. (“SOLV” or the “Company”) (Nasdaq: MWH), a leading provider of infrastructure services to the power industry, today announced that, in connection with its previously completed public offering of 15,000,000 shares of Class A common stock of the Company, including 7,698,410 shares being offered by affiliates of American Securities LLC (the “Selling Stockholders”) and 7,301,590 shares being offered by the Company, the underwriters have fully exercised their option to purchase an additional 2,250,000 shares of Class A common stock of the Company, including 1,154,760 shares from the Selling Stockholders and 1,095,240 from the Company at the public offering price of $36.00 per share, less underwriting discounts and commissions. The issuance and sale of the additional shares closed today.

Offering was led by B Group Capital with significant participation from, among others, Columbia Threadneedle Investments, Corbets Capital, Venture 76, and Mossrock Capital

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Badger Meter (BMI) To Contact Him Directly To Discuss Their Options

Vantage Acquisition Anchors HHH’s Transformation into a Diversified Holding Company

MINNEAPOLIS, June 03, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC) (“Celcuity” or the “Company”), a clinical-stage biotechnology company focused on the development of targeted therapies for the treatment of multiple solid tumor indications, today announced the pricing of its upsized underwritten public offering of $500,000,000 aggregate principal amount of its 0.250% convertible senior notes due 2032 (the “Convertible Notes”). The aggregate principal amount of the offering was increased from the previously announced offering size of $400,000,000.